[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy

References

• Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29: 2–9
   PubMed Web of Science ®Google Scholar
• Smith M R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–7368
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Kanelli S, Ansell S M, Habermann T M, Inwards D J, Tuinstra N, Witzig T E. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001; 42: 1329–1337
   PubMed Web of Science ®Google Scholar
• Leon R J, Gonsalvo A, Salas R, Hidalgo N C. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004; 79: 949, 953
   PubMed Web of Science ®Google Scholar
• Swords R, Power D, Fay M, O'Donnell R, Murphy P T. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004; 77: 103–104
   PubMed Web of Science ®Google Scholar
• Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348: 2690–2691, discussion 2690–2691
   PubMed Web of Science ®Google Scholar
• Montero A J, McCarthy J J, Chen G, Rice L. Acute respiratory distress syndrome after rituximab infusion. Int J Hematol 2005; 82: 324–326
   PubMed Web of Science ®Google Scholar
• Soubrier M, Jeannin G, Kemeny J L, Tournadre A, Caillot N, Caillaud D, et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008; 75: 362–365
   PubMed Web of Science ®Google Scholar
• Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004; 80: 164–167
   PubMed Web of Science ®Google Scholar
• Alexandrescu D T, Dutcher J P, O'Boyle K, Albulak M, Oiseth S, Wiernik P H. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45: 2321–2325
   PubMed Web of Science ®Google Scholar
• Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005; 81: 169–170
   PubMed Web of Science ®Google Scholar
• Ghesquieres H. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005; 16: 1399
   PubMed Web of Science ®Google Scholar
• Wagner S A, Mehta A C, Laber D A. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82: 916–919
   PubMed Web of Science ®Google Scholar
• Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Leuk Lymphoma 2006; 47: 1683–1685
   PubMed Web of Science ®Google Scholar
• Kim K M, Kim H C, Jeon K N, Kim H G, Kang J H, Hahm J R, et al. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 2008; 49: 155–158
   PubMed Web of Science ®Google Scholar
• Macartney C, Burke E, Elborn S, Magee N, Noone P, Gleadhill I, et al. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma 2005; 46: 1523–1526
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Lamb M R, Rodriguez G I, Scroggin C, Jr, Greco F A. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003; 4: 36–42
   PubMedGoogle Scholar
• Biehn S E, Kirk D, Rivera M P, Martinez A E, Khandani A H, Orlowski R Z. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 2006; 24: 234–237
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, Naparstek E. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006; 6: 407–409
   PubMedGoogle Scholar
• Nieuwenhuizen L, Verzijlbergen F J, Wiltink E, Grutters J C, Biesma D H. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma. Haematologica 2008; 93: 1267–1269
   PubMed Web of Science ®Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Malik S W, Myers J L, DeRemee R A, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851–1856
   PubMed Web of Science ®Google Scholar
• Lee Y, Kyung S Y, Choi S J, Bang S M, Jeong S H, Shin D B, et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006; 21: 183–186
   PubMedGoogle Scholar
• Meissner H H, Soo Hoo G W, Khonsary S A, Mandelkern M, Brown C V, Santiago S M. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration 2006; 73: 197–202
   PubMed Web of Science ®Google Scholar
• Tateishi U, Hasegawa T, Seki K, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organising pneumonia: semi-quantitative evaluation using computed tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33: 906–912
   PubMed Web of Science ®Google Scholar
• Kazama T, Faria S C, Uchida Y, Ito H, Macapinlac H A. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med 2008; 22: 111–114
   PubMed Web of Science ®Google Scholar
• Han H S, Escalon M P, Hsiao B, Serafini A, Lossos I S. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009; 20: 309–318
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Hamlin H P, Hoewitz S M, Noy A, O'Connor O A, Palomba M L, et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood (ASH Annual Meeting Abstracts) 2006; 108: 161a
   Google Scholar
• Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224
   PubMed Web of Science ®Google Scholar
• van der Kolk L E, Grillo-Lopez A J, Baars J W, Hack C E, van Oers M H. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115: 807–811
   PubMed Web of Science ®Google Scholar
• Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001; 2: 378–384
   PubMedGoogle Scholar